Rate Video

ICML 2019 | Cami-T in R/R cHL: analysis of clinical determinants of safety and efficacy

Alexandre Hirayama

Hodgkin Lymphoma Lymphoma Antibodies Camidanlumab tesirine

Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the analysis of the clinical determinants for the safety and effiacy of camidanlumab tesirine (Cami-T; ADCT-301) for relapsed/refractory classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Recent publication on the impact of response to lymphodepletion on PFS in NHL

Alexandre Hirayama • 20 Jun 2019

Durable responses after CD19 CAR-T plus ibrutinib in CLL

Alexandre Hirayama • 20 Jun 2019

Related Videos

Novel therapies in the pipeline at Cellectis

Roman Galetto • 14 May 2022

The promise of antibody-drug conjugates for the treatment of multiple myeloma

Mohamad Mohty • 13 May 2022

CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCL

Natalie Grover • 28 Apr 2022

CD30, a promising target for CAR-T therapy in Hodgkin lymphoma

Natalie Grover • 28 Apr 2022